|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS12139 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-SLC5A8 |
| 克隆性 | 是 |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human SLC5A8 |
產(chǎn)品訂購信息：
英文名稱 Anti-SLC5A8
中文名稱 鈉碘轉(zhuǎn)運(yùn)體蛋白8抗體品牌
別 名 AIT; Apical iodide transporter; Electrogenic sodium monocarboxylate cotransporter; SC5A8_HUMAN; SLC5A8; SMCT; SMCT1; sodium coupled monocarboxylate transporter 1; Sodium iodide related cotransporter; Sodium iodide-related cotransporter; Sodium-coupled monocarboxylate transporter 1; solute carrier family 5 iodide transporter member 8; Solute carrier family 5 member 8.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Cow
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡
蛋白分子量 predicted molecular weight: 67kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SLC5A8
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
鈉碘轉(zhuǎn)運(yùn)體蛋白8抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate and alpha-ketoisocaproate), with a Na(+):substrate stoichiometry of between 4:1 and 2:1. Catalyzes passive carrier mediated diffusion of iodide. Mediates iodide transport from the thyrocyte into the colloid lumen through the apical membrane. May be responsible for the absorption of D-lactate and monocarboxylate drugs from the intestinal tract. Acts as a tumor suppressor, suppressing colony formation in colon cancer, prostate cancer and glioma cell lines. May play a critical role in the entry of L-lactate and ketone bodies into neurons by a process driven by an electrochemical Na(+) gradient and hence contribute to the maintenance of the energy status and function of neurons.
Function : Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate and alpha-ketoisocaproate), with a Na(+):substrate stoichiometry of between 4:1 and 2:1. Catalyzes passive carrier mediated diffusion of iodide. Mediates iodide transport from the thyrocyte into the colloid lumen through the apical membrane. May be responsible for the absorption of D-lactate and monocarboxylate drugs from the intestinal tract. Acts as a tumor suppressor, suppressing colony formation in colon cancer, prostate cancer and glioma cell lines. May play a critical role in the entry of L-lactate and ketone bodies into neurons by a process driven by an electrochemical Na(+) gradient and hence contribute to the maintenance of the energy status and function of neurons.
Subcellular Location : Apical cell membrane; Multi-pass membrane protein.
Tissue Specificity : Expressed in normal thyroid, localized at the apical pole of thyroid cells facing the colloid lumen, but expression profoundly decreased in thyroid carcinomas. Expressed in normal colon but absent in colon aberrant crypt foci and colon cancers. Present in normal kidney cortex, brain, prostate, gastric mucosa and breast tissue but was significantly down-regulated in primary gliomas, gastric cancer, prostate tumors and breast tumors.
Similarity : Belongs to the sodium:solute symporter (SSF) (TC 2.A.21) family.
Database links : UniProtKB/Swiss-Prot: Q8N695.2
環(huán)指蛋白41 多克隆抗體 RNF41 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
環(huán)指蛋白5 多克隆抗體 RNF5 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
環(huán)指蛋白6 多克隆抗體 RNF6 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
環(huán)指蛋白81 多克隆抗體 RO52 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
異質(zhì)性胞核核糖核蛋白A0 多克隆抗體 ROA0 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
真核翻譯起始因子2C4抗體 組蛋白H3-K9甲基轉(zhuǎn)移酶抗體
Rho GTP酶激活蛋白15抗體 組蛋白H3K9甲基轉(zhuǎn)移酶4抗體
基因結(jié)合蛋白ARID1B抗體 組蛋白H3 K9甲基轉(zhuǎn)移酶抗體
E3連接酶蛋白ARIH2抗體 組蛋白H2B抗體
ADP核糖基化樣因子1抗體 組蛋白H2B.s抗體
組蛋白H3 (Di Methyl Lys79) 單克隆抗體(Q7) Histone H3 (Di Methyl Lys79) Monoclonal Antibody(Q7) 700/30ul#1540/100ul#2520/200ul
組蛋白H3 (Tri Methyl Lys36) 單克隆抗體(Q12) Histone H3 (Tri Methyl Lys36) Monoclonal Antibody(Q12) 700/30ul#1540/100ul#2520/200ul
Oct1 單克隆抗體 Oct1 Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
CD16 單克隆抗體 CD16 Monoclonal Antibody 700/30ul#1540/100ul#2520/200ul
組蛋白H3 (Tri Methyl Lys79) 單克隆抗體(3G3) Histone H3 (Tri Methyl Lys79) Monoclonal Antibody(3G3) 700/30ul#1540/100ul#2520/200ul
蒼耳Xanthium sibiricum p-Menth-8-ene-1,2-diol 1-羥基異二氫葛縷醇 57457-97-3 C10H18O2 ≥95%
大車前苷ThqccglycosidqHPLC≥98%，20mg/支
安芐青每素 安芐西林三水酸、安芐青每素三水酸、三水安芐西林、三水合安芐青每素、水合安芐青每素 Ampicillin 7177-48-2 ≥98.5% HPLC
含量測(cè)定愈創(chuàng)甘油醚100528-200401常溫，避光50mg
Iodixanol 典克沙醇標(biāo)準(zhǔn)品92339-11-2 2
鈉碘轉(zhuǎn)運(yùn)體蛋白8抗體品牌異土木香內(nèi)酯 Isoalantolactone (≥98%,HPLC) 23720-80-1 20MG 標(biāo)準(zhǔn)品
掌葉防己 Jaorrhiza palmate( DC.)Miers 大黃藤素 3486-67-7 C21H22NO4+ ≥98% 亮丙瑞林 - 對(duì)照譜圖(L0 76001
Curcumin姜黃素458-37-720mg/支
人皮膚參考顯微照片標(biāo)準(zhǔn)品ea
香葉子樹Lindera sychnifolia Bi-linderone none 1227375-09-8 C34H32O10 ≥95%
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 鈉碘轉(zhuǎn)運(yùn)體蛋白8抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）鈉碘轉(zhuǎn)運(yùn)體蛋白8抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
